Evidence map›Paper›PMID 33774187›Full record

ArticleAnnals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology2021

Why are immune adverse events so common with checkpoint inhibitor therapy?

Taras Lyubchenko, Donald Y M Leung, Elena Goleva

Abstract read
In one paragraph

Article in Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Effect of immune checkpoint inhibitors on asthma.Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology · 2022
    Article
  5. Our current understanding of checkpoint inhibitor therapy in cancer immunotherapy.Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Taras LyubchenkoDepartment of Pediatrics, National Jewish Health, Denver, Colorado; Department of Biological Sciences, University of Denver, Colorado. Electronic address: lyubchenkot@njhealth.org.
Donald Y M LeungDepartment of Pediatrics, National Jewish Health, Denver, Colorado.
Elena GolevaDepartment of Pediatrics, National Jewish Health, Denver, Colorado.

Funding

SEAL (Stopping Atopic dermatitis and ALlergy) Study: Prevent allergy by enhancing the skin barrierU01AI147462 · NIAID · STANFORD UNIVERSITY · PI Mary Johnson, GIDEON LACK · 2020 to 2026
$14.0M
Identification of pathways to mitigate Immune-Related Adverse Events with Cancer Immunotherapy U01AR077511 · NIAMS · NATIONAL JEWISH HEALTH · PI KERN, JEFFREY A, LACOUTURE, MARIO · 2020 to 2024
$3.1M
NIAID NIH HHS U01 AI147462NIAMS NIH HHS U01 AR077511
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AnimalsAntineoplastic Agents, ImmunologicalAutoimmunityHumansImmune Checkpoint InhibitorsImmunotherapyNeoplasmsReceptors, Antigen, T-CellT-LymphocytesAntineoplastic Agents, ImmunologicalImmune Checkpoint InhibitorsReceptors, Antigen, T-Cell

Identifiers

PMID33774187
PMCPMC8670739

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.